# US 12,600,969 B2 · Expression control using a regulatable intron > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,600,969 B2 - Document ID: US12600969B2 - Status: Granted - Kind: B2 - Application number: 17/981,146 - Filed: 2022-11-04 - Published: 2023-09-28 - Granted: 2026-04-14 - Earliest claimed: 2017-08-23 - Assignees: Askbio Inc. - Applicants: Askbio Inc. - Inventors: Graham Whyteside - Web page: https://patentgrep.com/patent/US12600969B2 ## CPC - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression - A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid} - C12N 15/85: for animal cells - C12N 2320/30: Special therapeutic applications - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to the use of a regulatory nucleic acid sequences that are able to regulate gene expression in eukaryotic cells and which are responsive to the unfolded protein response (UPR). There are disclosed regulatable introns and UPR-inducible promoters, which are able to regulate gene expression. There are also disclosed recombinant expression constructs comprising such regulatory nucleic acid sequences, whereby expression of the encoded expression product can be induced by invoking the unfolded protein response (UPR) in a eukaryotic cell containing the construct, methods of using such constructs and associated vectors, cells and suchlike. ## Claims ### Claim 1 A synthetic nucleic acid expression construct comprising a nucleic acid comprising a sequence encoding an expression product, the sequence encoding an expression product comprising a sequence which encodes a regulatable intron, said regulatable intron being an intron which comprises an excisable sequence which is capable of being spliced out of a transcript produced from the synthetic expression construct via the unfolded protein response (UPR) system in the cell, thereby resulting in a transcript encoding a functional expression product, wherein the regulatable intron comprises the sequence CNG/CNG-Xn-CNG/CNG, wherein Xn represents a sequence of length n bases, wherein/represents a cleavage site and wherein the sequence CNG-Xn-CNG is excised from the transcript; or wherein the regulatable intron comprises the sequence CNG/CNG-Xn-CNG/CNG, wherein Xn represents a sequence of length n nucleotides, wherein/represents the cleavage site such that the excisable sequence CNG-Xn-CNG is excised from the transcript upon splicing, and wherein the nucleotide at the 5′ end of the sequence Xn is a C or G, and wherein the expression product is not the XBP1 protein, Hac1 protein, bZIP60 protein or a homologue thereof. ### Claim 2 (depends on 1) A vector comprising the synthetic nucleic acid expression construct of claim 1. ### Claim 3 (depends on 1) A cell comprising the nucleic acid expression construct of claim 1. ### Claim 4 (depends on 3) The cell of claim 3, wherein the cell is a eukaryotic cell. ### Claim 5 (depends on 3) The cell according to claim 3 wherein the nucleic acid expression construct encodes an expression product that is toxic to the cell. ### Claim 6 (depends on 1) A method for producing an expression product, the method comprising: a) providing a population of eukaryotic cells comprising a synthetic nucleic acid expression construct according to according to claim 1; b) treating said population of cells so as to induce the unfolded protein response, thereby inducing splicing of the excisable sequence out of the regulatable intron; c) incubating said population of cells under suitable conditions for production of the expression product; and d) isolating the expression product from said population of cells. ### Claim 7 (depends on 6) The method according to claim 6 which comprises incubating said population of cells under conditions suitable for growth of the cells prior to step b) of treating said population of cells so as to induce the unfolded protein response (UPR). ### Claim 8 (depends on 6) The method according to claim 6 wherein step b) comprises applying a stress to said cells, said stress being suitable to induce the UPR, or wherein step b) comprises administering a chemical agent that is able to induce the UPR in said cells. ### Claim 9 (depends on 8) The method according to claim 8 wherein the chemical agent that is able to induce the UPR in said cells comprises one or more of forskolin, dithiothreitol (DTT), tunicamycin, thapsigargin, a saturated fatty acid, an agent that is able to downregulate stearoyl-CoA desaturase enzyme activity. ### Claim 10 (depends on 6) The method according to claim 6 wherein step b) comprises expressing an inducer protein in said population of eukaryotic cells so as to induce the UPR response in the population of cells, or wherein step b) comprises transfecting said population of cells with an expression vector that is capable of expressing an inducer protein, preferably a heterologous protein, in said cells, or wherein step b) comprises inducing expression of the inducer protein from an expression vector that was previously introduced into the cells. ### Claim 11 (depends on 6) The method according to claim 6 wherein step b) comprises exposing the cells to hypoxia or carbohydrate deprivation. ### Claim 12 (depends on 6) The method according to claim 6 wherein the population of cells comprises fungal cells, animal cells, or plant cells, preferably wherein the population of cells comprises mammalian cells. ### Claim 13 (depends on 6) The method according to claim 6 which comprises, prior to step a), the step of introducing the nucleic acid expression construct into the cells. ### Claim 14 (depends on 1) A method for gene therapy in a subject in need of said gene therapy comprising: -introducing into the subject a gene therapy vector comprising a nucleic acid expression construct according to claim 1, the nucleic acid expression construct comprising a sequence encoding a therapeutic expression product such that the gene therapy vector delivers the nucleic acid expression construct to target cells of the subject; and expressing a therapeutically effective amount of the functional therapeutic expression product in target cells of subject.